These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 25835097)

  • 21. Symptom management.
    O'Connor P
    Adv Neurol; 2006; 98():227-55. PubMed ID: 16400837
    [No Abstract]   [Full Text] [Related]  

  • 22. Spasticity, ataxia and fatigue in multiple sclerosis.
    Kesselring J; Thompson AJ
    Baillieres Clin Neurol; 1997 Oct; 6(3):429-45. PubMed ID: 10101582
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of Sativex(®) on quality of life and activities of daily living in patients with multiple sclerosis spasticity.
    Arroyo R; Vila C; Dechant KL
    J Comp Eff Res; 2014 Jul; 3(4):435-44. PubMed ID: 25275238
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Cannabis medicines in Norway--the basis for approval].
    Gramstad L; Sagabråten AS
    Tidsskr Nor Laegeforen; 2012 Dec; 132(23-24):2598-9. PubMed ID: 23338087
    [No Abstract]   [Full Text] [Related]  

  • 25. Multiple sclerosis spasticity management--key publications.
    Gold R
    Expert Rev Neurother; 2013 Dec; 13(12 Suppl):47-8. PubMed ID: 24289843
    [No Abstract]   [Full Text] [Related]  

  • 26. Spasticity modified by obturator nerve block.
    Felsenthal G
    Md State Med J; 1979 Sep; 28(9):123-6. PubMed ID: 502600
    [No Abstract]   [Full Text] [Related]  

  • 27. Multiple sclerosis. Treatment.
    Champion de Crespigny JV
    Aust Fam Physician; 1979 Feb; 8(2):163-8. PubMed ID: 426733
    [No Abstract]   [Full Text] [Related]  

  • 28. New insights in the pathophysiology and treatment of multiple sclerosis spasticity and related symptoms. Foreword.
    Montalbán X
    Expert Rev Neurother; 2011 Apr; 11(4 Suppl):1. PubMed ID: 21449852
    [No Abstract]   [Full Text] [Related]  

  • 29. Multiple sclerosis spasticity symptoms management. Endocannabinoid system modulator data beyond clinical trials. Foreword.
    Trojano M
    Expert Rev Neurother; 2013 Feb; 13(3 Suppl 1):1. PubMed ID: 23369052
    [No Abstract]   [Full Text] [Related]  

  • 30. Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis.
    Collin C; Davies P; Mutiboko IK; Ratcliffe S;
    Eur J Neurol; 2007 Mar; 14(3):290-6. PubMed ID: 17355549
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Editorial. Spasticity in multiple sclerosis].
    Vermersch P
    Rev Neurol (Paris); 2012 Apr; 168 Suppl 3():S35. PubMed ID: 22721362
    [No Abstract]   [Full Text] [Related]  

  • 32. Does giving segmental muscle vibration alter the response to botulinum toxin injections in the treatment of spasticity in people with multiple sclerosis? A single-blind randomized controlled trial.
    Paoloni M; Giovannelli M; Mangone M; Leonardi L; Tavernese E; Di Pangrazio E; Bernetti A; Santilli V; Pozzilli C
    Clin Rehabil; 2013 Sep; 27(9):803-12. PubMed ID: 23543344
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of the safety and tolerability profile of Sativex: is it reassuring enough?
    Wade D
    Expert Rev Neurother; 2012 Apr; 12(4 Suppl):9-14. PubMed ID: 22509986
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex(®) ), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis.
    Novotna A; Mares J; Ratcliffe S; Novakova I; Vachova M; Zapletalova O; Gasperini C; Pozzilli C; Cefaro L; Comi G; Rossi P; Ambler Z; Stelmasiak Z; Erdmann A; Montalban X; Klimek A; Davies P;
    Eur J Neurol; 2011 Sep; 18(9):1122-31. PubMed ID: 21362108
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Repetitive transcranial magnetic stimulation of the motor cortex ameliorates spasticity in multiple sclerosis.
    Centonze D; Koch G; Versace V; Mori F; Rossi S; Brusa L; Grossi K; Torelli F; Prosperetti C; Cervellino A; Marfia GA; Stanzione P; Marciani MG; Boffa L; Bernardi G
    Neurology; 2007 Mar; 68(13):1045-50. PubMed ID: 17389310
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Total knee replacement in patients with multiple sclerosis.
    Shannon FJ; Cogley D; Glynn M
    Knee; 2004 Dec; 11(6):485-7. PubMed ID: 15581769
    [TBL] [Abstract][Full Text] [Related]  

  • 37. What place for ▾ cannabis extract in MS?
    Drug Ther Bull; 2012 Dec; 50(12):141-4. PubMed ID: 23241565
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MObility ImproVEment with spasticity in multiple sclerosis in Europe: the MOVE 1 EU study.
    Vermersch P
    Neurodegener Dis Manag; 2014; 4(6):407-15. PubMed ID: 25531685
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Successful management of multiple sclerosis and persistent vegetative state requires frequent reassessment.
    Henkel G
    J Am Med Dir Assoc; 2003; 4(4 Suppl):H23-4. PubMed ID: 12857365
    [No Abstract]   [Full Text] [Related]  

  • 40. [Kinetometric demonstration of the antispastic action of a GABA derivative (Ciba 34647-BA)].
    Mutani R; Fariello R; Quattrocolo G; Delsedime M
    Riv Neurol; 1971; 41(3):143-51. PubMed ID: 5126431
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.